BioMarin

In News

BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 - PR Newswire

PR Newswire - Jun 16, 2026

BioMarin Pharmaceutical (BMRN) Stock Could Be 36.7% Undervalued After ENDO 2026 Data - simplywall.st

simplywall.st - Jun 16, 2026

Why Do I Pheel This Way? Episode 2 Explores Social Life, Support and Self-Advocacy for Teens with Phenylketonuria - BioMarin Pharmaceutical

BioMarin Pharmaceutical - Jun 11, 2026

BioMarin presents three-year VOXZOGO data for hypochondroplasia - Investing.com

Investing.com - Jun 16, 2026

BioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments - marketscreener.com

marketscreener.com - Jun 16, 2026

BioMarin notches win in study that could expand use of top-selling medicine - BioPharma Dive

BioPharma Dive - May 21, 2026

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance

Yahoo Finance - May 23, 2026

Vosoritide data support planned FDA submission for hypochondroplasia - Contemporary Pediatrics

Contemporary Pediatrics - Jun 16, 2026

BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal - Fierce Biotech

Fierce Biotech - May 18, 2026

BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer - Fierce Pharma

Fierce Pharma - May 12, 2026

Kim Warner Builds Pathways for Early-Career Professionals | BioMarin - BioMarin Pharmaceutical

BioMarin Pharmaceutical - May 29, 2026

BioMarin Announces Board Leadership Transition - PR Newswire

PR Newswire - Apr 21, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment